Avinger

Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat. The company was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avinger reports Q1 revenue growth, secures China partnership for expansion

Avinger's Q1 2024 performance showed revenue growth but challenges in profitability.
Strategic partnerships and product development present growth opportunities.
Financial restructuring and cost management are crucial for future success.

Avinger reports improved Q3 performance and strategic growth initiatives

Avinger's Q3 2024 performance showed operational improvements and cost-saving initiatives, leading to reduced losses.
The company's strategic partnerships and focus on innovation position them for growth opportunities in the medical device market.
While challenges persist, Avinger's progress in commercialization and partnerships signal a path towards financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2023 after the close of trading on Wednesday, March 20, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce Full Year 2023 Results on March 20, 2024

HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. This partnership includes an exclusive right to Zylox-Tonbridge to localize, manufacture, and commercialize the entire product family developed by Avinger in Greater China (including Mainland China, Hong Kong, Taiwan, and Macau), and a technology transfer agreement to leverage Zylox-Tonbridge cost-efficient manufacturing capacity to support Avinger's global sales outside of Greater China.

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA / ACCESSWIRE / March 6, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced a new strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, "Zylox-Tonbridge"), a leading medical device company in the neuro- and peripheral-vascular interventional market in China.

Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge

Avinger (AVGR) came out with a quarterly loss of $2.92 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to loss of $11.54 per share a year ago.

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

Avinger, Inc. (NASDAQ:AVGR ) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Operator Greetings. Welcome to the Avinger Third Quarter 2023 Results Conference Call.

Avinger, Inc. (AVGR) Q3 2023 Earnings Call Transcript

REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2023. Third Quarter and Recent Highlights Third quarter revenue of $1.8 million, and gross margin of 21% Initiated full commercial launch for Tigereye ST, Avinger's most advanced image-guided CTO-crossing device, in September Commenced limited launch of the new Pantheris LV (large vessel) image-guided atherectomy device Advanced development of the first-ever image-guided coronary CTO-crossing system, including successful completion of additional animal and cadaver heart studies, in preparation for IDE submission anticipated mid-2024 Named Phil Preuss to new position of Chief Commercial Officer in October, to lead sales force expansion and drive revenue growth initiatives Released updated, best-in-class interim data from the Pantheris SV IMAGE-BTK (below-the-knee) study in key opinion leader presentation at the AMP clinical conference Strengthened balance sheet through conversion of $1.9 million or 12% of outstanding debt to a new series of convertible preferred stock, and raising net proceeds of $5.1 million through the sale of common stock in the company's at-the-market (ATM) facility "With full commercial launch of our Tigereye ST CTO-crossing catheter and limited launch of our new Pantheris LV image-guided atherectomy system in the third quarter, exciting new clinical outcomes data for our Pantheris SV below-the-knee atherectomy device, and the outstanding performance and increased mobility of our Lightbox 3 imaging console launched last year, we have built the most advanced peripheral products portfolio in the industry," commented Jeff Soinski, Avinger's President and CEO.

Avinger Reports Third Quarter 2023 Results

REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce Third Quarter 2023 Results on October 26

Strengthens Balance Sheet in Support of Tigereye ST Launch and Coronary Product Development REDWOOD CITY, CA / ACCESSWIRE / September 27, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that is has raised gross proceeds of approximately $5.3 million through its at-the-market (ATM) facility in September 2023, selling an aggregate of 596,200 shares of common stock at a weighted average price of $8.97. Net proceeds from the transactions were approximately $5.2 million after deducting sales commissions.

Avinger Raises $5.3 Million via At-The-Market Facility

Shares of Avinger Inc. skyrocketed 63.5% on heavy volume in morning trading Monday, enough to make them the biggest gainers trading on major U.S. exchanges, after the medical device company announced the commercial launch of its Tigereye ST, an image-guided catheter-based system for the diagnosis and treatment of vascular disease. Trading volume soared to 26.5 million shares, compared with the full-day average of about 9,300 shares.

Avinger stock rockets off a record low after launch of vascular disease treatment system

REDWOOD CITY, CA / ACCESSWIRE / September 18, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of its Tigereye® ST next generation image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, all current and prospective accounts can now order the Tigereye ST device.

Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device

REDWOOD CITY, CA / ACCESSWIRE / August 24, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced three podium presentations featuring the company's Lumivascular technology at The Amputation Prevention Symposium, held from August 16 through August 19 in Chicago, Illinois. AMP focuses on education and technologies for treating critical limb ischemia, an advanced stage of PAD, in patients facing a life-altering amputation.

Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023

REDWOOD CITY, CA / ACCESSWIRE / August 4, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. ("CRG") into shares of a new series of convertible preferred stock.

Avinger Announces Conversion of 12% of CRG Term Debt into Equity

Avinger, Inc. (NASDAQ:AVGR ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Avinger Second Quarter 2023 Results Call.

Avinger, Inc. (AVGR) Q2 2023 Earnings Call Transcript

Avinger (AVGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.94 per share a year ago.

Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates

REDWOOD CITY, CA / ACCESSWIRE / July 27, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2023. Second Quarter and Recent Highlights Second quarter revenue of $2.0 million, and gross margin of 30% Received 510(k) clearance and initiated limited launch for Tigereye ST, Avinger's next generation image-guided CTO-crossing device, with full commercial launch anticipated in the third quarter Received 510(k) clearance for the new Pantheris LV (large vessel) image-guided atherectomy device, and initiated limited launch in the third quarter Advanced development of the first-ever image-guided coronary CTO-crossing system through successful completion of the first round of animal studies and preparing for a second round of animal studies at a leading clinical center in the third quarter Continued to generate excellent clinical outcomes data in the treatment of advanced disease in the Pantheris SV IMAGE-BTK study (small vessel, below-the-knee), with full enrollment expected to be completed in the third quarter Avinger's technology, products and clinical data featured in multiple key opinion leader (KOL) presentations at the Charing Cross, New Cardiovascular Horizons and LINC clinical conferences, with additional podium presentations scheduled at the AMP conference in August "We received 510(k) clearance for two exciting new devices in the second quarter, completing development of the most advanced peripheral products portfolio in the industry, and providing the opportunity for two important new product launches in the second half of this year," commented Jeff Soinski, Avinger's President and CEO.

Avinger Reports Second Quarter 2023 Results

REDWOOD CITY, CA / ACCESSWIRE / July 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce Second Quarter 2023 Results on July 27

REDWOOD CITY, CA / ACCESSWIRE / June 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2023, which took place June 6 through June 9. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany.

Avinger Announces Presentations by Key Opinion Leaders at LINC 2023

REDWOOD CITY, CA / ACCESSWIRE / June 9, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place May 30 through June 2 in New Orleans. Key opinion leaders in the fields of interventional cardiology and endovascular interventions highlighted Avinger's Lumivascular technology in the following sessions: Dr. Ian Cawich, an interventional cardiologist at Arkansas Heart in Little Rock, highlighted the entire portfolio of Avinger's proprietary OCT-guided atherectomy technologies in his session, "OCT-Guided Atherectomy of ATK and BTK Lesions.

Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference

REDWOOD CITY, CA / ACCESSWIRE / June 7, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Pantheris® LV, its next-generation image-guided atherectomy system for the treatment of peripheral artery disease (PAD). Pantheris LV is designed for treatment in larger vessels, such as the SFA and popliteal arteries, where the majority of PAD procedures are performed today.

Avinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy System

REDWOOD CITY, CA / ACCESSWIRE / June 5, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the successful completion of the first clinical cases with the new Tigereye ST image-guided CTO crossing system. Dr. Ian Cawich, an interventional cardiologist at Arkansas Heart Hospital, and Dr. Jaafer Golzar, an interventional cardiologist at Advocate Christ Medical Center and Avinger's Chief Medical Officer, performed the first cases with the new system.

Avinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion (CTO) Crossing Device

Avinger, Inc. (NASDAQ:AVGR ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps – Darrow Associates Investor Relations Jeff Soinski – Chief Executive Officer Nabeel Subainati – Principal Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Greetings, and welcome to the Avinger First Quarter 2023 Results Call.

Avinger, Inc. (AVGR) Q1 2023 Earnings Call Transcript

REDWOOD CITY, CA / ACCESSWIRE / May 10, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2023. First Quarter and Recent Highlights First quarter revenue of $1.9 million, and gross margin of 34% Received 510(k) clearance for Tigereye ST, Avinger's next generation image-guided CTO-crossing device, and initiated limited launch activities in the second quarter Filed a 510(k) submission for the new Pantheris LV (large vessel) image-guided atherectomy device and advanced the review process Continued to expand penetration of Lightbox 3 next-generation imaging console in both new and existing clinical accounts Advanced development of the first-ever image-guided coronary CTO-crossing system, with initial animal studies expected to be completed in the second quarter Pantheris SV IMAGE-BTK clinical study (small vessel, below-the-knee) continues to generate excellent clinical outcomes data in a challenging patient population Announced the physician presentation of unsurpassed clinical data on the treatment of in-stent restenosis with Pantheris at the Charing Cross International Symposium, with additional podium presentations planned for major clinical conferences in the second quarter Maintained a cash position of $10.4 million at March 31, 2023 "We sustained solid operations in the first quarter, significantly improving gross margin from the prior year and maintaining our efficient operating cost model as we moved forward with multiple product and clinical programs designed to expand and enhance Avinger's growth opportunities," commented Jeff Soinski, Avinger's President and CEO.

Avinger Reports First Quarter 2023 Results

REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the first quarter 2023 after the close of trading on Wednesday, May 10, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce First Quarter 2023 Results on May 10

REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England. The CX Symposium is a leading vascular and endovascular education conference focused on education, innovation, and evidence.

Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium

Bionano Genomics

Cepton

Crown ElectroKinetics

Penny stocks to buy for under $1 but are they worth the risk this week? The post Top Penny Stocks To Buy?

News for Avinger Stock (AVGR)